Pfizer Torcetrapib Filing To Start ‘Dialogue,’ Not Necessarily Standard Review

Pfizer views its planned filing for its investigational HDL/LDL cholesterol combination therapy torcetrapib/Lipitor as the initiation of a dialogue between the company and FDA, not necessarily the start of a standard review